- Home
- CLDI vs BCDA Comparison
CLDI vs BCDA Comparison
Compare CLDI & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- BCDA
- Stock Information
- Founded
- CLDI 2014
- BCDA N/A
- Country
- CLDI United States
- BCDA United States
- Employees
- CLDI N/A
- BCDA N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- BCDA Health Care
- Exchange
- CLDI Nasdaq
- BCDA Nasdaq
- Market Cap
- CLDI 10.2M
- BCDA 10.1M
- IPO Year
- CLDI N/A
- BCDA N/A
- Fundamental
- Price
- CLDI $0.71
- BCDA $2.39
- Analyst Decision
- CLDI
- BCDA Strong Buy
- Analyst Count
- CLDI 0
- BCDA 1
- Target Price
- CLDI N/A
- BCDA $25.00
- AVG Volume (30 Days)
- CLDI 41.3M
- BCDA 230.7K
- Earning Date
- CLDI 08-12-2025
- BCDA 08-12-2025
- Dividend Yield
- CLDI N/A
- BCDA N/A
- EPS Growth
- CLDI N/A
- BCDA N/A
- EPS
- CLDI N/A
- BCDA N/A
- Revenue
- CLDI N/A
- BCDA $3,000.00
- Revenue This Year
- CLDI N/A
- BCDA N/A
- Revenue Next Year
- CLDI N/A
- BCDA N/A
- P/E Ratio
- CLDI N/A
- BCDA N/A
- Revenue Growth
- CLDI N/A
- BCDA N/A
- 52 Week Low
- CLDI $0.20
- BCDA $1.63
- 52 Week High
- CLDI $3.89
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- CLDI 65.65
- BCDA 58.67
- Support Level
- CLDI $0.23
- BCDA $1.98
- Resistance Level
- CLDI $1.60
- BCDA $2.45
- Average True Range (ATR)
- CLDI 0.15
- BCDA 0.17
- MACD
- CLDI 0.07
- BCDA 0.04
- Stochastic Oscillator
- CLDI 36.55
- BCDA 88.00
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).